

PRESS CLIPPING SHEET

PUBLICATION:	Egyptian Gazette
DATE:	01-May-2016
COUNTRY:	Egypt
CIRCULATION:	60,000
TITLE :	Boehringer Ingelheim to introduce its first diabetes treatment to the Egyptian market
PAGE:	05
ARTICLE TYPE:	Health Corporate News
REPORTER:	Staff Report

PRESS CLIPPING SHEET

Boehringer Ingelheim to introduce its first diabetes treatment to the Egyptian market

BOEHRINGER Ingelheim (BI), a leading pharmaceutical company, held a scientific gathering attended by more than 500 endocrinologist, internal medicine and primary care physicians from all over Egypt, to introduce Boehringer Ingelheim first DPP-4 inhibitor drug for patients of T2D in Egypt.

Along with the scientific event, the company raised the awareness about the importance of adopting safe and effective treatment programmes for patients while assisting them understand their disease. The event was aimed at providing a platform for encouraging informative discussion and sharing insights regarding the efficacy of DPP4 inhibitors including the new introduced drug, Linagliptin, as a treatment option for people with Type 2 diabetes.

Diabetes is a life-long disease that affects the way a human's body handles glucose, in their blood. T2D is the most common form of diabetes often leading to chronic complications like cardiovascular disease, kidney disease, and nerve damage. Increasing incidence of diabetes is putting people at an increasing risk of developing these complications. Dr. Mohamed el-Sahhar,



(From L to R) Dr. Hesham el-Hefnawy, Dean of Egypt National Institute for Diabetes and Endocrinology, Professor Mohamed Khattab, professor of medicine and diabetes at Cairo university, Dr. Inass Shaltout, Professor of Internal Medicine, Cairo University and Dr. Mohamed el-Sahhar, Boehringer Ingelheim Country Head of Egypt.

Boehringer Ingelheim Country Head of Egypt, stated: "At Boehringer Ingelheim, we strongly believe in the importance of investing in research and development. Our main focus is to provide an innovative approach to managing T2D, and we are building upon our commitment to meet the diverse needs of people with diabetes. Through research and collaboration, our efforts reflect a growing range of product portfolios and a continued determination to provide sustainable solutions to diabetic

patients in Egypt, not only through providing treatments, but also by collaborating with government, institutions and healthcare providers to serve patients according to their needs."

According to the International Diabetes Federation (IDF), there were over 35.4 million cases of diabetes in the MENA region in 2015, with 7.8 million of them located in Egypt. IDF also found that in the same year, there were 78,184 deaths in Egyptian adults due to the condition.